Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Interest & Investment Income (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Interest & Investment Income data on record, last reported at -$552000.0 in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 112.42% year-over-year to -$552000.0; the TTM value through Sep 2025 reached $9.5 million, down 39.73%, while the annual FY2024 figure was $17.4 million, 264.5% up from the prior year.
  • Interest & Investment Income reached -$552000.0 in Q3 2025 per DNTH's latest filing, down from $2.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.7 million in Q2 2024 and bottomed at -$552000.0 in Q3 2025.
  • Average Interest & Investment Income over 4 years is $2.1 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: soared 596.7% in 2024, then plummeted 112.42% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $640000.0 in 2022, then skyrocketed by 281.88% to $2.4 million in 2023, then soared by 63.26% to $4.0 million in 2024, then tumbled by 113.83% to -$552000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were -$552000.0 in Q3 2025, $2.3 million in Q2 2025, and $3.8 million in Q1 2025.